Roche (OTCMKTS:RHHBY) Upgraded at Argus

Key Points

• Argus upgraded Roche (OTCMKTS:RHHBY) from a "hold" to a "buy" rating in a note to investors on Monday.
• Analyst coverage is mixed—five Buys, five Holds and one Sell—giving an average rating of "Hold" with a consensus price target of $57.00, while the stock opened at $49.85.
• Key technicals: 50-day moving average $54.72, 200-day moving average $49.92, and a one-year range of $34.75 to $60.85.

Roche (OTCMKTS:RHHBY - Get Free Report) was upgraded by equities researchers at Argus from a "hold" rating to a "buy" rating in a note issued to investors on Monday.

Several other research firms have also recently issued reports on RHHBY. Citigroup assumed coverage on shares of Roche in a report on Tuesday, January 27th. They set a "buy" rating for the company. TD Cowen reiterated a "hold" rating on shares of Roche in a research report on Tuesday, February 10th. The Goldman Sachs Group raised Roche from a "sell" rating to a "hold" rating in a report on Thursday, January 15th. Morgan Stanley restated an "underweight" rating on shares of Roche in a research note on Wednesday, February 4th. Finally, Wolfe Research reaffirmed an "outperform" rating on shares of Roche in a report on Thursday, February 26th. Five research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $57.00.

Roche Stock Performance

RHHBY stock opened at $49.85 on Monday. The company has a fifty day moving average of $54.72 and a 200-day moving average of $49.92. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.12 and a current ratio of 1.38. Roche has a one year low of $34.75 and a one year high of $60.85.

Institutional Investors Weigh In On Roche

Hedge funds and other institutional investors have recently modified their holdings of the stock. Curio Wealth LLC acquired a new stake in shares of Roche in the 3rd quarter worth approximately $25,000. Oakworth Capital Inc. acquired a new position in Roche during the third quarter worth $57,000. Salomon & Ludwin LLC boosted its position in Roche by 256.6% during the third quarter. Salomon & Ludwin LLC now owns 2,853 shares of the company's stock worth $129,000 after purchasing an additional 2,053 shares in the last quarter. Atlas Capital Advisors Inc. acquired a new stake in Roche in the fourth quarter valued at $192,000. Finally, Douglass Winthrop Advisors LLC purchased a new position in shares of Roche in the third quarter valued at $201,000.

About Roche

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.